

**DISEASE BURDEN**

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

**CLINICAL RELEVANCE**

Presented at CROI 2024, the new Cabotegravir Ultra Long Acting (ULA) formulation exhibits a PK profile that supports dose intervals of approximately 4 months. CAB-ULA has the potential for less frequent dosing and may reduce clinic visits. CAB-ULA IM Q4M is progressing into upcoming late-stage HIV-1 PrEP and treatment studies. Limited data show a favorable safety profile. CAB-ULA IM was better tolerated than SC.

**INTELLECTUAL PROPERTY LANDSCAPE**

Primary patents on cabotegravir have been granted in many LMICs and are expected to expire in 2026. Secondary patents on the ultra long-acting formulations have not yet been made public.

**SERVICE DELIVERY ENABLERS**

Assessment in progress

**REGULATORY**

Assessment in progress

**MANUFACTURING**

Assessment in progress

**MARKET**

Assessment in progress

